A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies

NCT02118337 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

97

Enrollment

INDUSTRY

Sponsor class

Conditions

Select Advanced Malignancies
Kidney Cancer
Clear Cell Renal Cell Carcinoma

Interventions

BIOLOGICAL: MEDI0680
BIOLOGICAL: Durvalumab
BIOLOGICAL: Nivolumab

Sponsor

MedImmune LLC